The RealReal, Stitch Fix, and Target appeal to the issues most important to today’s shoppers. That will make them the success stories of the future.
Buy online/pickup in store, omnichannel experiences, and inventory control are three ways retailers can strengthen their performance -- in earnings reports and on the market.
New treatments for breast cancer, multiple sclerosis, and others make the drugmaker's stock a more compelling buy in 2020.
Impossible Foods is just one rival that will soon serve up more plant-based offerings, and that might take a bite out of Beyond Meat’s margins.
The company will lead consumers into the future with products like its smart toothbrush and diaper monitor.
The company needs more than the gift of holiday sales to keep the shares moving higher as challenges remain in the new year.
An upcoming FDA decision on Aimmune’s first drug could set the tone for the rest of its pipeline.
Shareholders in the athletic apparel and footwear maker were rewarded in 2019. Those who own one of its big retail partners could be next.
Victoria’s Secret, long linked to models in angel wings, doesn’t speak to today’s buyer. That may continue to hurt L Brands’ earnings and share price.
Struggling retailer The Gap might benefit by following H&M’s seamless online and in-store revamp.
DNA sequencing giant Illumina dropped a deal that would have brought it complementary technology. Going it alone might be a better bet for the company and investors.
“Buy online, pick up in store” was music to shoppers’ ears over the holidays, and the department store chain led the orchestra.
Amazon’s shares didn’t do much in 2019, but growth in Prime and control over its own deliveries could make the stock one to watch in 2020.
Party City is making efforts to mitigate a bad year, but it still may be too early to celebrate.
A plan to connect with consumers, smooth out the buying experience, and control inventory may bring the once-iconic brand back into the spotlight.
The children's apparel seller has had a market-beating 2019, but it's not too late for investors to add it to their portfolios.
With a newly approved drug and a candidate treatment that the FDA has given its “breakthrough” designation, there's good reason to expect revenue growth.
The “Oprah effect” sent Dr. Phil to stardom, but it won’t drive WW share recovery unless the company’s other efforts can lift sales and subscriptions.
H&M’s online makeover is on its way to transforming share performance.
After investors' lukewarm reaction to the company's fiscal second quarter results -- is now the time for investors to buy the stock?